Generic Drug Cos. Push To Ax FTC Pay-For-Delay Suit

Law360, New York (March 4, 2014, 7:10 PM EST) -- Par Pharmaceutical Cos. Inc. and Paddock Laboratories Inc. urged a Georgia federal judge on Monday to nix the Federal Trade Commission's pay-for-delay case against them, saying their patent settlement was protected under Noerr-Pennington antitrust immunity.

The two generic drugmakers hit back at the FTC's efforts to convince the court not to use the immunity to dismiss the case. Par and Paddock, backed by fellow defendant AbbVie Products LLC, maintain that their Hatch-Waxman Act settlement over testosterone replacement treatment Androgel qualified for the immunity because a federal...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.